PUBLISHER: The Business Research Company | PRODUCT CODE: 1942484
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942484
A brain mapping instrument is a device designed to visualize, measure, and analyze both the structure and function of the brain. Utilizing various technologies, these instruments offer detailed images and data on brain activity, connectivity, and anatomy. They play a crucial role in neuroscience research, clinical diagnosis, and treatment planning.
Key products in brain mapping include computed axial tomography (CAT), positron emission tomography, electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), and functional magnetic resonance imaging (fMRI). Computed Axial Tomography (CAT), also known as Computed Tomography (CT), is an advanced imaging technique that employs X-rays and computer processing to create highly detailed cross-sectional images of the body's internal structures. This technique is a significant diagnostic tool in modern healthcare. The available procedures encompass both invasive and non-invasive devices, serving various end users such as hospitals and ambulatory centers.
Tariffs are affecting the brain mapping instruments market by increasing import costs for imaging hardware, electronic assemblies, detector modules, superconducting magnets, and precision optical components that are sourced globally for ct, pet, eeg, fnirs, and fmri systems. The financial impact is particularly visible across high-field mri platforms, hybrid pet/ct scanners, and advanced eeg systems manufactured in North America, Europe, and Asia-Pacific technology hubs that rely on cross-border component supply. Hospitals and ambulatory centers are experiencing longer procurement cycles, price revisions, and budget constraints as tariff-driven cost escalations move across OEMs and distributors. At the same time, tariffs are encouraging regional manufacturing partnerships, localized component production, and domestic assembly initiatives, which may improve long-term supply resilience and ecosystem competitiveness.
The brain mapping instruments market research report is one of a series of new reports from The Business Research Company that provides brain mapping instruments market statistics, including brain mapping instruments industry global market size, regional shares, competitors with a brain mapping instruments market share, detailed brain mapping instruments market segments, market trends and opportunities, and any further data you may need to thrive in the brain mapping instruments industry. This brain mapping instruments market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The brain mapping instruments market size has grown strongly in recent years. It will grow from $2.42 billion in 2025 to $2.58 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to growth in neurological disorder diagnosis programs, increasing utilization of eeg and ct-based brain mapping systems, early adoption of neuroimaging tools in hospital and research centers, expansion of brain activity monitoring in clinical neurology, rising investment in neuroscience research infrastructure.
The brain mapping instruments market size is expected to see strong growth in the next few years. It will grow to $3.33 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to rising demand for fmri and pet-based functional brain mapping, increasing uptake of hybrid and high-resolution imaging systems, higher adoption of non-invasive mapping solutions in ambulatory settings, growing integration of multimodal brain analysis tools, expanding application of brain mapping in precision medicine and neurotherapeutics. Major trends in the forecast period include increasing adoption of advanced neuroimaging and brain activity monitoring technologies, growing use of brain mapping instruments in clinical diagnosis and treatment planning, expansion of brain mapping applications in neuroscience and cognitive research, rising preference for non-invasive and patient-friendly brain mapping procedures, focus on enhancing imaging accuracy, data quality, and diagnostic efficiency.
The rising prevalence of neurological disorders is expected to drive the growth of the brain mapping instrument market in the coming years. Neurological disorders are conditions impacting the brain, spinal cord, and nerves, leading to symptoms such as movement difficulties, cognitive decline, and sensory impairments, with examples including Alzheimer's, Parkinson's, epilepsy, multiple sclerosis, and stroke. The increase in neurological disorders is attributed to factors such as an aging population, urbanization, lifestyle shifts, advancements in diagnostic technologies, and various environmental and infectious risk factors. Brain mapping instruments play a crucial role in both clinical practice and research, providing valuable insights into neurological conditions and supporting personalized treatment approaches. For example, in March 2023, the Alzheimer's Association, a U.S.-based nonprofit health organization, reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia, a neurological disorder. Furthermore, the number of Americans aged 65 and older with Alzheimer's dementia is projected to rise to 13.8 million by 2060. Thus, the increasing prevalence of neurological disorders is propelling the growth of the brain mapping instrument market.
Major companies operating in the brain mapping instruments market are focusing on sensing-enabled adaptive neuromodulation, such as BrainSense-enabled closed-loop deep brain stimulation (DBS), to deliver more precise and personalized neurological therapy. Sensing-enabled adaptive neuromodulation systems integrate real-time brain signal detection with stimulation delivery, allowing therapy to dynamically respond to a patient's neural activity. BrainSense technology is a neuro-interface embedded in DBS systems that records local field potentials (LFPs) from targeted brain regions, analyzes these signals, and automatically adjusts stimulation parameters in real time. This closed-loop approach helps optimize therapeutic outcomes while minimizing side effects associated with overstimulation. For instance, in February 2025, Medtronic, a US-based medical technology company, introduced its BrainSense Adaptive DBS system following FDA approval. The system features real-time self-adjusting stimulation, a BrainSense Electrode Identifier that rapidly determines the optimal electrode contact, and personalized closed-loop therapy that adapts both in clinical environments and during patients' daily activities, enhancing treatment precision and quality of life for individuals with neurological disorders.
In May 2025, Firefly Neuroscience, Inc., a US-based artificial intelligence company developing brain-health solutions, acquired Evoke Neuroscience, Inc. for approximately US$6 million, comprising 50% cash, 50% Firefly common stock, and up to an additional US$0.5 million in earn-out payments. With this acquisition, Firefly significantly expanded its proprietary brain-wave (EEG/ERP) data assets, intellectual property portfolio, and commercial presence, strengthening its ability to accelerate the development of a foundational AI model of the human brain. Evoke Neuroscience, Inc. is a US-based medical device company that provides FDA-cleared hardware and software platforms for comprehensive EEG and event-related potential (ERP)-based brain health assessments.
Major companies operating in the brain mapping instruments market are Siemens Healthineers, GE Healthcare, Philips Healthcare, Elekta AB, Nihon Kohden Corporation, Brainlab AG, Natus Medical Incorporated, Hitachi Medical Systems, Canon Medical Systems Corporation, Compumedics Limited, Medtronic PLC, Magstim Company Limited, EB Neuro S.p.A., Brain Products GmbH, Soterix Medical Inc., Rogue Research Inc., NIRx Medical Technologies LLC, Neurosoft, Artinis Medical Systems, Gowerlabs Ltd.
North America was the largest region in the brain mapping instruments market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the brain mapping instruments market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the brain mapping instruments market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The brain mapping instruments market consists of sales of electroencephalography (EEG) systems, magnetoencephalography (MEG) systems, near-infrared spectroscopy (NIRS) systems, magnetic resonance spectroscopy (MRS) systems, and optogenetics tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Brain Mapping Instruments Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses brain mapping instruments market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for brain mapping instruments ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The brain mapping instruments market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.